Highlights

  • VB0004 is being developed for idiopathic pulmonary fibrosis, a progressive lung disease.
  • The company describes VB0004 as a VIP mimetic and NPR-C agonist.
  • The completed Phase 1a program informs the proposed next clinical stage.
  • On 30 September 2026, the company reported acceptance of a US FDA pre-IND meeting request.
  • FDA written responses were expected in mid-November 2026, according to the company.

Vectus Biosystems Limited (ASX:VBS) develops investigational small-molecule medicines directed at fibrotic disease, in which excess scar tissue can interfere with organ function. Its lead compound, VB0004, is being advanced for idiopathic pulmonary fibrosis (IPF). During 2026, Vectus Biosystems Limited (ASX:VBS) concentrated on regulatory engagement and preparation for further clinical investigation following completion of a Phase 1a safety study.

VB0004 and the IPF Development Program

VB0004 is described by the company as a vasoactive intestinal peptide (VIP) mimetic and natriuretic peptide receptor-C (NPR-C) agonist. These terms refer to the biological pathways through which the investigational molecule is intended to act. Its proposed use in IPF remains under clinical development; the mechanism does not establish that the treatment reverses lung scarring in patients.

Vectus Biosystems Limited (ASX:VBS) identifies an adaptive Phase 1b/2a trial in people with IPF as the next planned clinical phase. Such a study would help assess the treatment in the intended patient population. Trial design, safety evaluation and endpoints remain important aspects of the regulatory process, and the planned trial should not be presented as completed or approved.

September 2026 FDA Meeting Development

On 30 September 2026, Vectus Biosystems Limited (ASX:VBS) announced that the US Food and Drug Administration had granted its request for a Type B pre-Investigational New Drug meeting concerning VB0004 in IPF. The company said the interaction would involve written responses to questions about its proposed development program. This represents an opportunity for regulatory feedback, not marketing authorisation or confirmation of clinical efficacy.

The company expected detailed FDA written responses by mid-November 2026 and said it would finalise and submit its meeting package with assistance from its US regulatory agent. These are stated expectations as of the September announcement, rather than confirmation that the responses have been received or the submissions completed.

Pipeline Scope and Clinical Considerations

Beyond VB0004, the company describes a library of more than 200 molecules directed at fibrotic and cardiometabolic conditions. Vectus Biosystems Limited (ASX:VBS) has not established commercial approval for its lead IPF therapy on the basis of the development information discussed here. Further clinical evidence will be needed to clarify safety, dosing and efficacy in the relevant disease population.

Fibrosis research carries several uncertainties, including whether preclinical findings translate into clinical outcomes, how participants respond to treatment, and the time required for regulatory review. Research spending and access to funding also matter because clinical programs may extend across multiple reporting periods. No unverified funding runway, revenue figure or projected trial result is assumed here.

Key Insights

Vectus Biosystems Limited (ASX:VBS) made a documented regulatory step in September 2026 when its FDA pre-IND meeting request was granted. The principal distinction is between a program entering regulatory discussion and a therapy supported by completed patient efficacy trials. VB0004 remains investigational, with the proposed next clinical stage and subsequent disclosures providing the relevant context for assessing the company’s development progress.